テネシーにおける脂肪肝の臨床試験
テネシー内の拠点で、脂肪肝に関する7件の研究が参加者を募集しています。
テネシー内の都市
公式研究テキスト（英語）
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Cordova
- 89bio Clinical Study Site, Hermitage
- 89bio Clinical Study Site, Nashville
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/10/05更新 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Chattanooga
- 89bio Clinical Study Site, Cordova
- 89bio Clinical Study Site, Hermitage
- 他1件
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/10/05更新 · NCT06318169A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Galen Medical Group - Galen Hepatology, Chattanooga
- Gastro One (Walnut Run Road), Cordova
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Clarksville
- Akero Clinical Study Site, Hermitage
- Akero Clinical Study Site, Nashville
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/21更新 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, Chattanooga
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/09/17更新 · NCT07221188A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, Hermitage
被験者募集中第2相
18歳〜70歳 · 全性別 · 2026/08/03更新 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, Chattanooga
被験者募集中第3相
18歳〜75歳 · 全性別 · 2026/07/27更新 · NCT07221227ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。